• Expanding existing agreements with leading healthcare networks
• Signing new commercial contracts with top academic medical centers
• Installed base of 50 revenue-generating sites with 643 additional opportunities

Cyclopharm Ltd (ASX: CYC) is pleased to provide an update on accelerating commercial momentum for its Technegas technology in the United States. The company is leveraging existing institutional relationships to drive network expansion and multi-site adoption, reinforcing a more repeatable and scalable growth model across key health system networks. Recent wins include expanded agreements with Mass General Brigham, University of North Carolina Health System, Emory Health Care, and the Joseph Maxwell Cleland Atlanta VA Medical Center. Cyclopharm has also signed new commercial contracts with the Medical University of South Carolina and Stony Brook University Health System, representing the company's first installations in South Carolina and strengthening its presence in the New York market. In total, Cyclopharm's US footprint now includes 50 revenue-generating installations linked to an additional 331 contracted locations, with a further 74 primary installations and 103 associated secondary locations in the contracting/installation phase. The company has also engaged with approximately one quarter of the 5,139 US sites performing nuclear medicine lung imaging. Cyclopharm notes the inclusion of Technegas in the draft US and international clinical guideline for ventilation-perfusion imaging, which is expected to further accelerate clinical adoption and institutional uptake across the US.

Cyclopharm expects the finalisation and publication of the clinical guidelines for ventilation-perfusion imaging, which recognise Technegas as a preferred ventilation imaging agent, to further accelerate clinical adoption, utilisation and institutional uptake of Technegas across the US, adding to the current growing commercial momentum.